HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

AC 93253

a SIRT2 inhibitor and antineoplastic agent; structure in first source

Also Known As:

AC-93253; AC93253

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - Benzothiazoles: 40
        AC 93253: 2
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzothiazoles: 40
      - AC 93253: 2

Experts

1.	Chen, Huei-Wen: 1 article (11/2017)
2.	Chen, Jeremy J W: 1 article (11/2017)
3.	Lai, Yi-Hua: 1 article (11/2017)
4.	Lin, Sih-Yin: 1 article (11/2017)
5.	Wu, Yu-Shan: 1 article (11/2017)
6.	Dastych, Jaroslaw: 1 article (07/2015)
7.	Gorzkiewicz, Michal: 1 article (07/2015)
8.	Karwaciak, Iwona: 1 article (07/2015)
9.	Pulaski, Lukasz: 1 article (07/2015)
10.	Ratajewski, Marcin: 1 article (07/2015)

Related Diseases

1.	Neoplasms (Cancer) 11/13/2017 - "Furthermore, AC-93253 iodide significantly suppressed cancer cell proliferation, colony formation, invasion, and migration in vitro and tumor growth in vivo. " 11/13/2017 - "The effects of AC-93253 iodide on cancer cell colony formation, invasion, and migration were assessed in PC9 and PC9/gef cells. " 11/13/2017 - "AC-93253 iodide sensitized tumor cells to gefitinib treatment regardless of whether the cells were gefitinib-sensitive (PC9) or resistant (H1975 and PC9/gef), indicating that it may exert synergistic effects when used in combination with established therapeutic agents. "
2.	Melanoma (Melanoma, Malignant) 07/05/2015 - "AC-93253 triggers the downregulation of melanoma progression markers and the inhibition of melanoma cell proliferation." 07/05/2015 - "Taken together, we conclude that the usage of AC-93253 in combined therapy could be a promising strategy for melanoma patients. " 07/05/2015 - "Furthermore, melanoma cells exposed to AC-93253 and doxorubicin displayed altered biological responses, including apoptosis and proliferation, compared to cells exposed to single treatments. " 07/05/2015 - "Here, we show for the first time that AC-93253, a SIRT2 inhibitor, exerts a negative effect on the expression of a set of genes involved in the progression and chemoresistance (e.g., oncogenes, apoptosis-related genes, ABC transporter genes, and cell cycle control genes) of melanoma cells. "
3.	Lung Neoplasms (Lung Cancer) 11/13/2017 - "Our findings also suggested that the inhibitory effects of AC-93253 iodide on lung cancer progression may be attributable to its ability to modulate multiple proteins, including Src, PI3K, JNK, Paxillin, p130cas, MEK, ERK, and EGFR. "
4.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/13/2017 - "Human non-small cell lung cancer (NSCLC) cell lines (PC9, PC9/gef, A549, and H1975) with different EGFR statuses were tested by cytotoxicity and proliferation assays after AC-93253 iodide treatment. "

Related Drugs and Biologics

1.	Sirtuin 2
2.	Paxillin
3.	Mitogen-Activated Protein Kinase Kinases (MEKs)
4.	ATP-Binding Cassette Transporters (ABC Transporters)
5.	Proteins (Proteins, Gene)
6.	Iodides
7.	Doxorubicin (Adriamycin)
8.	Gefitinib (Iressa)

Related Therapies and Procedures

1.	Therapeutics